|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MTRNR2L1 |
Gene summary for MTRNR2L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MTRNR2L1 | Gene ID | 100462977 |
| Gene name | MT-RNR2 like 1 | |
| Gene Alias | HN1 | |
| Cytomap | 17p11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | P0CJ68 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100462977 | MTRNR2L1 | HCC1_Meng | Human | Liver | HCC | 4.78e-05 | -1.90e-01 | 0.0246 |
| 100462977 | MTRNR2L1 | HCC2_Meng | Human | Liver | HCC | 4.62e-37 | 2.94e-01 | 0.0107 |
| 100462977 | MTRNR2L1 | cirrhotic1 | Human | Liver | Cirrhotic | 8.96e-06 | 1.52e-01 | 0.0202 |
| 100462977 | MTRNR2L1 | cirrhotic2 | Human | Liver | Cirrhotic | 6.10e-24 | 5.20e-01 | 0.0201 |
| 100462977 | MTRNR2L1 | HCC1 | Human | Liver | HCC | 5.86e-59 | 7.50e+00 | 0.5336 |
| 100462977 | MTRNR2L1 | HCC2 | Human | Liver | HCC | 1.14e-07 | 7.94e-01 | 0.5341 |
| 100462977 | MTRNR2L1 | HCC5 | Human | Liver | HCC | 9.15e-40 | 1.35e+00 | 0.4932 |
| 100462977 | MTRNR2L1 | Pt13.a | Human | Liver | HCC | 1.07e-06 | -1.90e-01 | 0.021 |
| 100462977 | MTRNR2L1 | C04 | Human | Oral cavity | OSCC | 1.60e-13 | 3.62e-01 | 0.2633 |
| 100462977 | MTRNR2L1 | C30 | Human | Oral cavity | OSCC | 8.23e-53 | 2.09e+00 | 0.3055 |
| 100462977 | MTRNR2L1 | C46 | Human | Oral cavity | OSCC | 1.35e-03 | -6.74e-02 | 0.1673 |
| 100462977 | MTRNR2L1 | C08 | Human | Oral cavity | OSCC | 1.94e-17 | 4.35e-01 | 0.1919 |
| 100462977 | MTRNR2L1 | C86 | Human | Oral cavity | OSCC | 2.13e-05 | 1.03e+00 | 0.161 |
| 100462977 | MTRNR2L1 | LP17 | Human | Oral cavity | LP | 1.28e-02 | 1.48e-01 | 0.2349 |
| 100462977 | MTRNR2L1 | EOLP-1 | Human | Oral cavity | EOLP | 8.35e-04 | -1.54e-01 | -0.0202 |
| 100462977 | MTRNR2L1 | NEOLP-1 | Human | Oral cavity | NEOLP | 1.77e-03 | -1.54e-01 | -0.0194 |
| 100462977 | MTRNR2L1 | NEOLP-2 | Human | Oral cavity | NEOLP | 3.94e-04 | -1.54e-01 | -0.0196 |
| 100462977 | MTRNR2L1 | NEOLP-3 | Human | Oral cavity | NEOLP | 3.73e-03 | -1.54e-01 | -0.0191 |
| 100462977 | MTRNR2L1 | SYSMH1 | Human | Oral cavity | OSCC | 1.77e-03 | -1.54e-01 | 0.1127 |
| 100462977 | MTRNR2L1 | SYSMH2 | Human | Oral cavity | OSCC | 3.73e-03 | -1.54e-01 | 0.2326 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0097194 | Liver | HCC | execution phase of apoptosis | 48/7958 | 85/18723 | 6.47e-03 | 2.63e-02 | 48 |
| GO:1900117 | Liver | HCC | regulation of execution phase of apoptosis | 19/7958 | 29/18723 | 1.05e-02 | 3.89e-02 | 19 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |